Courtesy of SBHCI. The occurrence of a periprocedural neurological events is associated to an increased risk of death and morbidity at long term, both for transcatheter aortic valve replacement (TAVR) and for surgery. The SURTAVI study, recently presented at the ACC meeting and simultaneously published by NEJM, showed that TAVR with self-expandable CoreValve or Evolut<a href="https://solaci.org/en/2017/05/30/surtavi-sub-study-of-neurological-events-more-evidence-in-favor-of-tavr/" title="Read more" >...</a>
NOTION: TAVI with low risk at 4 year follow up
Courtesy of the SBHCI. There is little data about the use of transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis at low surgical risk. Many of the questions involve long term duration of valves (over 10 years) when treating younger patients with longer life expectancy. The NOTION study aims at comparing<a href="https://solaci.org/en/2017/05/30/notion-tavi-with-low-risk-at-4-year-follow-up/" title="Read more" >...</a>
ARTE: Aspirin or Aspirin and Clopidogrel after TAVR?
Courtesy of SBHCI. This study presented at Euro PCR and simultaneously published by JACC Cardiovascular Interventions poses a question that has remained unanswered since the start of TAVR. There is little information on the optimal antithrombotic therapy after transcatheter aortic valve replacement (TAVR). In general, patients receive between 1 and 6 months of dual<a href="https://solaci.org/en/2017/05/25/arte-aspirin-or-aspirin-and-clopidogrel-after-tavr/" title="Read more" >...</a>
Further Evidence on Managing Dysfunctioning Bioprostheses with Balloon-Expandable Prostheses
Early experience with the valve-in-valve technique in the treatment of failed bioprosthetic surgical valves in transcatheter aortic valve replacement (TAVR) has yielded acceptable acute procedural results. This turned the technique into another therapeutic option, one that could even cause the reassessment of the age limit for the surgical implantation of a mechanical or bioprosthesis valve.<a href="https://solaci.org/en/2017/05/17/further-evidence-on-managing-dysfunctioning-bioprostheses-with-balloon-expandable-prostheses/" title="Read more" >...</a>
TAVR: minimalist strategy Is favorable in severe COPD
Courtesy of Dr. Carlos Fava. The presence of chronic obstructive pulmonary disease (COPD) is a criterion for which patients are ruled out for surgery and proposed as candidates for its current alternative, transcatheter aortic valve replacement (TAVR). A minimalist strategy could benefit this patient group, given the use of conscious sedation instead of general anesthesia. <a href="https://solaci.org/en/2017/05/14/tavr-minimalist-strategy-is-favorable-in-severe-copd/" title="Read more" >...</a>
Post TAVR thrombosis, is it more common than we know?
Courtesy of Dr. Carlos Fava Few post TAVR scenarios remain to be analyzed. One of them is post TAVR valve thrombosis. This event has been reported in around 0.5% of cases, but its incidence, consequences and adequate treatment remain unclear. The study analyzed 642 patients undergoing TAVR. Patients were followed up with Doppler Echocardiography<a href="https://solaci.org/en/2017/04/25/post-tavr-thrombosis-is-it-more-common-than-we-know/" title="Read more" >...</a>
Diastolic Dysfunction: Shall We Begin to Assess It?
Courtesy of Dr. Carlos Fava. The association between diastolic dysfunction (DD) and aortic insufficiency (AI) after transcatheter aortic valve replacement (TAVR) has not been studied yet, but the presence of aortic regurgitation has proved to be associated with worse outcomes. A total of 144 out of 195 patients who underwent TAVR with balloon-expandable SAPIENS or SAPIENS XT<a href="https://solaci.org/en/2017/04/19/diastolic-dysfunction-shall-we-begin-to-assess-it/" title="Read more" >...</a>
Surgery or TAVR in intermediate risk? Results of the SURTAVI Study
Courtesy of Dr. Gustavo Leiva. Transcatheter aortic-valve replacement (TAVR) with the use of a self-expanding prosthesis is superior to medical therapy in patients with severe, symptomatic aortic stenosis in whom surgical aortic-valve replacement has been associated with prohibitive risk. Among patients considered at high risk, TAVR may be an alternative to surgery. The comparative<a href="https://solaci.org/en/2017/04/06/surgery-or-tavr-in-intermediate-risk-results-of-the-surtavi-study/" title="Read more" >...</a>
Percutaneous Repair of Paravalvular Leaks After TAVR: The Challenge of Identifying Eligible Subjects
Courtesy of Dr. Carlos Fava. This study enrolled 72 patients who underwent transcatheter aortic valve replacement with an Edwards Sapiens valve, and then experienced a leak of at least moderate severity. Fifteen of them underwent a percutaneous leak repair after identification of the leak mostly through the presence of symptoms. Both groups were similar. Patients who<a href="https://solaci.org/en/2017/04/06/percutaneous-repair-of-paravalvular-leaks-after-tavr-the-challenge-of-identifying-eligible-subjects/" title="Read more" >...</a>
MANTA Closure Device for large-bore arteriotomy closure: Is It Safe?
Courtesy of Dr. Agustín Vecchia. The number of transcatheter aortic valve replacements (TAVR) and the placement of aortic endoprosthesis and ventricular assist devices, among others, have grown exponentially worldwide in the last few years. In a short time, many of these procedures will surely become the new standard of care. Logically, this growth comes hand in hand<a href="https://solaci.org/en/2017/03/27/manta-closure-device-for-large-bore-arteriotomy-closure-is-it-safe/" title="Read more" >...</a>